A groundbreaking study has revealed that approximately 10% of individuals possess genetic variants associated with a condition known as GLP-1 resistance. This phenomenon involves these individuals producing elevated levels of the hormone GLP-1 (glucagon-like peptide-1), which is crucial for blood sugar regulation. However, the hormone's effectiveness appears diminished in their bodies.
While the research primarily examined blood sugar control, the implications for weight loss remain unclear. Medications like Ozempic and Wegovy are often prescribed at higher doses for obesity management compared to diabetes treatment, necessitating further investigation into how these genetic factors may influence weight loss results.
Published in Genome Medicine, this extensive study spanned a decade and included contributions from scientists across multiple countries. The research combined human and mouse experiments with analyses of data from clinical trials focused on diabetes treatments.
According to Anna Gloyn, DPhil, a professor at Stanford Medicine and a senior author of the study, "In some trials, individuals with these variants struggled to achieve lower blood glucose levels after six months of treatment." Identifying potential responders early could enhance patient care, moving diabetes treatment closer to precision medicine.
Markus Stoffel, MD, PhD, from ETH Zurich, served as the study's other senior author. The lead authors included Mahesh Umapathysivam, MBBS, DPhil, from Adelaide University, and Elisa Araldi, PhD, from the University of Parma.
Umapathysivam noted the vast variability in patient responses to GLP-1 medications, emphasizing the potential of genetic insights to improve treatment decisions.
Understanding GLP-1 Resistance
This research marks the first comprehensive exploration of GLP-1 resistance, although the precise causes remain elusive. Gloyn stated, "We have explored numerous possibilities but have yet to pinpoint the exact reason for this resistance."
The team focused on two genetic variants that impair the enzyme PAM (peptidyl-glycine alpha-amidating monooxygenase), which plays a key role in activating various hormones, including GLP-1.
Initial hypotheses suggested that individuals with the PAM variant would exhibit lower GLP-1 levels due to instability. Surprisingly, the study found these individuals had increased GLP-1 levels, yet their biological activity was compromised, necessitating higher hormone levels for similar effects.
Mouse Studies Validate Findings
To confirm their results, researchers collaborated with teams in Zurich, using mice lacking the PAM gene. These mice also displayed GLP-1 resistance, characterized by elevated hormone levels but ineffective blood sugar control.
While the study revealed significant insights, questions about weight loss outcomes and the broader implications for diabetes treatment remain. The research team believes that understanding genetic factors could lead to more effective therapies for those resistant to GLP-1 medications.
As Gloyn suggested, "The complexity of this issue may eventually lead to innovative treatments aimed at overcoming GLP-1 resistance, similar to advances made in addressing insulin resistance." This could pave the way for more personalized and effective diabetes management strategies in the future.